Table 5 Response to PD-1 inhibitors in 16 patients
PD-1 | Combined regimen | Best tumor response | Time to response (months) | Time to progression or the end of follow-up (months) | Initial recurrent site | Final disease status | Biomarker |
|---|---|---|---|---|---|---|---|
Nivolumab | Paclitaxel + surgery | CR | - | 7 | Vaginal vault | PR | PD-L1 staining positively |
Pembrolizumab | CPT11 + surgery | CR | 4 | 8 | Lung | CR | PD-1 staining positively |
Camrelizumab | Paclitaxel + cisplatin | CR | 4 | 5 | Lung | CR | |
Tislelizumab | Paclitaxel + cisplatin + surgery | CR | 3 | 4 | Lung | CR | |
Sintilimab | Paclitaxel + cisplatin | SD | - | 4 | Lung | PR | |
Pembrolizumab | Etoposide + cisplatin | PD | - | 3 | Lung | PD | |
Toripalimab | Paclitaxel + cisplatin | PD | - | 3 | Lung | PD | |
Nivolumab | Paclitaxel + cisplatin | SD | - | 3 | Liver | PD | |
Sintilimab | Paclitaxel + cisplatin | PD | - | 3 | Abdominal organs | PD | |
Tislelizumab/ Sintilimab | CPT11 + cisplatin/paclitaxel | PR | 6 | 10 | Pelvic organs | PD | |
Sintilimab | Etoposide + cisplatin | PD | - | 3 | Abdominal organs + cervicothoracic lymph nodes | PD | |
Pembrolizumab | CPT11 | PR | 2 | 14 | Abdominal organs + Lung | PD | |
Sintilimab | Paclitaxel | CR | 6 | 12 | Abdominal organs + pelvic organs + vaginal vault | CR | TMB-H |
Tislelizumab | Paclitaxel | PR | 3 | 3 | Bone | PR | |
Camrelizumab | CPT11 + ciaplatin | SD | - | 4 | Brian | SD | |
Sintilimab | Paclitaxel + cisplatin | SD | - | 3 | Brian | SD | PD-L1 staining positively |